: Despite the high rate of stopping, the overall survival and progression-free survival (estimated at 35 months) remained excellent. Real-World vs. Clinical Trials

: Both groups had roughly the same time (about 85–87 months) from their initial diagnosis until they started ibrutinib treatment. Clinical Implications

: For those who stopped the medication, the median time until they did so was only 7 months .

The search for a "616 KB" article points directly to a significant medical study titled